|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 15/11 | (2006.01) |
| C12Q 1/68 | (2006.01) | ||
| A01N 43/04 | (2006.01) | ||
| C07H 21/04 | (2006.01) | ||
| A61K 31/07 | (2006.01) |
| (11) | Number of the document | 2194128 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09015323.0 |
| Date of filing the European patent application | 2007-05-10 | |
| (97) | Date of publication of the European application | 2010-06-09 |
| (45) | Date of publication and mention of the grant of the patent | 2012-08-01 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 799458 | 2006-05-11 | US | |
| 817203 | 2006-06-27 | US | |
| 840089 | 2006-08-25 | US | |
| 829914 | 2006-10-18 | US | |
| 901134 | 2007-02-13 | US |
| (72) |
Tan, Pamela, DE
Bramlage, Birgit, DE
Frank-Kamenetsky, Maria, US
Fitzgerald, Kevin, US
Akinc, Akin, US
Kotelianski, Victor, E., US
|
| (73) |
Alnylam Pharmaceuticals Inc.,
300 Third Street, Cambridge, MA 02142,
US
|
| (54) | Compositions and methods for inhibiting expression of the PCSK9 gene |
| Compositions and methods for inhibiting expression of the PCSK9 gene |